OptimizeRx Corp. (OPRX) intrinsic value & 10-year financials
OptimizeRx Corp. (OPRX) has a Graham intrinsic value of $8.97 per share. At $8.50 on Oct 17, 2026, the stock trades 5% below that value. Over the last 10 fiscal years revenue grew 34.2% a year to $109.4M, with an average return on invested capital of -7.0%.
- Graham intrinsic value
- $8.97
- Share price (Oct 17, 2026)
- $8.50
- Price vs Graham value
- 5% below
- Market cap
- $161.5M
- Revenue (FY2025)
- $109.4M
- Revenue growth (10-yr CAGR)
- 34.2%
- ROIC (10-yr avg)
- -7.0%
- Free cash flow (FY2025)
- $18.7M
OPRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $109.4M | $5.1M | $0.27 | $18.7M | 10.7% | 6.5% |
| FY2024 | $92.1M | -$20.1M | -$1.10 | $4.8M | -14.9% | -9.6% |
| FY2023 | $71.5M | -$17.6M | -$1.03 | -$7.3M | -36.9% | -14.3% |
| FY2022 | $1.0M | -$11.4M | -$0.64 | $10.6M | -1199.1% | -14.8% |
| FY2021 | $4.5M | $378.1K | $0.02 | $625.7K | 8.0% | 0.9% |
| FY2020 | $43.3M | -$2.2M | -$0.15 | -$6.4M | -4.9% | -6.7% |
| FY2019 | $24.6M | -$3.1M | -$0.23 | -$1.7M | -15.0% | -10.9% |
| FY2018 | $21.2M | $226.3K | $0.02 | $758.2K | 0.8% | — |
| FY2017 | $12.1M | -$2.1M | -$0.21 | -$1.5M | -17.6% | — |
| FY2016 | $7.8M | -$1.5M | — | -$644.4K | -20.4% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
OptimizeRx Corp is a consistent compounder, expanding top-line revenue at 34.2% annually over the past decade.
OptimizeRx Corp has historically struggled to out-earn its cost of capital, averaging just -7.0% ROIC.
OptimizeRx Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, OptimizeRx Corp is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $8.97 per share.